Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia.
The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. Clinical efficiency of afala was comparable with the efficiency of Serenoa repens extract (reference preparation).
Savel'eva
K V
KV
Materia Medica Holding Research-and-Production Company, Moscow.
Kachanova
M V
MV
Pavlov
V N
VN
Kazikhinurov
R A
RA
Frolov
M Yu
MY
Mukhin
A B
AB
Udut
V V
VV
Yurmazov
Z A
ZA
Dugina
Yu L
YL
Sergeeva
S A
SA
Epshtein
O I
OI
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
D000906:Antibodies; D007155:Immunologic Factors; C533336:afala